| Compound | Ara-290 (Cibinetide) |
|---|---|
| Category | Erythropoietin-derived trophic peptide |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Ara-290 (Cibinetide) — a erythropoietin-derived trophic peptide — sits in the "Clinical-stage" tier of this catalog. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
An 11-amino-acid peptide derived from erythropoietin, engineered to retain tissue-protective (non-erythropoietic) activity. It has completed human trials for neuropathic conditions.
Mechanism of Action
Cibinetide engages the innate repair receptor complex that mediates erythropoietin’s tissue-protection signaling without stimulating red blood cell production — the property that made it clinically interesting for neuropathy.
Research and Evidence
Small randomized trials in sarcoidosis-related small-fiber neuropathy reported improvements in neuropathic symptoms, and studies in diabetic neuropathy have been conducted. Development has not yet produced an approved product.
Safety and Side Effects
Trials to date have reported a generally tolerable profile, but the full safety database remains limited relative to approved medicines.
Frequently Asked Questions
What is the evidence tier of Ara-290 (Cibinetide)?
Ara-290 (Cibinetide) is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Ara-290 (Cibinetide) an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Ara-290 (Cibinetide)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered cibinetide / ARA-290 studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.